GSK GB0009252882

Report

Delayed London Stock Exchange - 09/10 11:35:02 am
1419.6	GBX		-0.50%

09/09	GLAXOSMITHKLINE ( '') (FORM 6 K : GlaxoSmithKline plc (the 'Company') (Form 6-K)	PU
09/09	FTSE 100 Drops as Pharma, Commodities Fall	DJ
09/09	ALECTOR : First Patient Dosed in Mid-Stage Study of Alector, GlaxoSmithKline's AL001 to Treat Amyotrophic Lateral Sclerosis	MT

Company

Business Summary

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

Number of employees : 94 066 people.

Sales per Business

	2019		2020		Delta
Pharmaceuticals	17 554.00	52%	17 056.00	50%	-2.84%
Consumer Healthcare	8 995.00	26.6%	10 033.00	29.4%	+11.54%
Vaccines	7 157.00	21.2%	6 982.00	20.5%	-2.45%
Corporate and Other Unallocated	48.00	0.1%	28.00	0.1%	-41.67%
GBP in Million

Sales per region

	2019		2020		Delta
United States	13 890.00	41.2%	14 556.00	42.7%	+4.79%
Rest of World	11 795.00	34.9%	11 379.00	33.4%	-3.53%
Europe	7 127.00	21.1%	7 184.00	21.1%	+0.8%
United Kingdom	942.00	2.8%	980.00	2.9%	+4.03%
GBP in Million

Managers

Name	Title	Age	Since
Emma Walmsley	Chief Executive Officer & Executive Director	51	2017
Iain Mackay	Chief Financial Officer & Executive Director	59	2019
Karenann Terrell	Chief Digital & Technology Officer	58	2017
Hal Barron	Executive Director & Chief Scientific Officer	57	2018
Jon Ellis	VP & Head-Technology Business Development	53	2019
Amy Altshul	SVP-Legal, Research & Development	-	-
Romulo Colindres	VP-Global Medical Affairs Lead for Zoster	49	-
Lynn Laverty Elsenhans	Independent Non-Executive Director	63	2012
Urs Rohner	Independent Non-Executive Director	61	2015
Manvinder Singh Banga	Senior Independent Non-Executive Director	65	2016

Members of the board

Name	Title	Age	Since
Jonathan Symonds	Non-Executive Chairman	61	2019
Emma Walmsley	Chief Executive Officer & Executive Director	51	2017
Lynn Laverty Elsenhans	Independent Non-Executive Director	63	2012
Urs Rohner	Independent Non-Executive Director	61	2015
Manvinder Singh Banga	Senior Independent Non-Executive Director	65	2016
Jesse Goodman, Dr.	Independent Non-Executive Director	68	2016
Vivienne Cox	Independent Non-Executive Director	61	2016
Laurie H. Glimcher, Dr.	Independent Non-Executive Director	68	2017
Hal Barron	Executive Director & Chief Scientific Officer	57	2018
Iain Mackay	Chief Financial Officer & Executive Director	59	2019

Equities

	Vote	Quantity	Free-Float		Company-owned shares		Total Float
Stock A	1	5,386,937,397	4,967,334,973	92.2%	355,205,950	6.6%	92.2%

Shareholders

Name	Equities	%
The Vanguard Group, Inc.	150,670,045	2.99%
BlackRock Fund Advisors	131,211,690	2.61%
Norges Bank Investment Management	118,407,000	2.35%
Dodge & Cox	99,377,874	1.98%
Capital Research & Management Co. (Global Investors)	81,548,399	1.62%
BlackRock Advisors (UK) Ltd.	69,533,000	1.38%
Schroder Investment Management Ltd.	67,567,287	1.34%
State Street Global Advisors Ltd.	66,555,001	1.32%
Threadneedle Asset Management Ltd.	58,881,313	1.17%
Silchester International Investors LLP	56,966,000	1.13%

Holdings

Name	Equities	%	Valuation
LYELL IMMUNOPHARMA, INC. (LYEL)	30,253,189	12.5%	438,671,241 USD
GLAXOSMITHKLINE PAKISTAN LIMITED (GLAXO)	263,029,794	82.6%	260,246,939 USD
VIR BIOTECHNOLOGY, INC. (VIR)	6,626,027	5.10%	236,217,863 USD
GLAXOSMITHKLINE S.A.E (BIOC)	76,161,378	91.2%	176,868,807 USD
GLAXOSMITHKLINE CONSUMER HEALTHCARE PAKISTAN LIMITED (GSKCH)	100,423,259	85.8%	148,032,922 USD
THERAVANCE BIOPHARMA, INC. (TBPH)	9,644,807	13.4%	125,189,595 USD
BICYCLE THERAPEUTICS LIMITED	1,616,295	7.59%	51,074,922 USD
DONG-A SOCIO HOLDINGS CO., LTD. (A000640)	409,693	6.47%	44,700,259 USD
FULCRUM THERAPEUTICS, INC. (FULC)	1,785,714	5.46%	13,053,569 USD
ALLERGY THERAPEUTICS PLC (AGY)	10,118,000	1.58%	3,777,151 USD

Markets and indexes

- Main Market

- FTSE 100 / FTSE 350, FTSE All-Share, FTSE Eurotop 100, Low Carbon 100 Europe, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200, Stoxx UK 50

Stock Exchange Codes


- Bloomberg Code :	GSK:LN
- Reuters Code :	GSK.L
- Datastream Code :	GSK

Company contact information

GlaxoSmithKline plc
980 Great West Road
TW8 9GS Brentford, Greater London

Phone : +44 (0)20 8047 5000
Fax : +44 (0)20 8047 7807
web site : http://www.gsk.com